Hadassah

Cell Cure Neurosciences Receives Grant of $1.33 Million From Israel's Office of the Chief Scientist

Wednesday, Aug 8 2012

Cell Cure Neurosciences Ltd., whose Chief Scientific Officer is Hadassah University Medical Center's Prof. Benjamin Reubinoff--Director of the its Human Embryonic Stem Cell Research Center--received a 1.3 million-dollar grant from Israel's Office of the Chief Scientist (OCS) to help finance its development of a treatment for age-related macular degeneration (AMD).

Cell Cure, established in 2005, manufactures diverse cell products, sourced from clinical-grade human embryonic stem cells. Its current programs include developing cells for the treatment of macular degeneration, Parkinson's disease, and cells potentially useful in treating multiple sclerosis. Cell Cure's plan for its cell-based product, OpRegen(R) includes filing an application to commence human clinical trials in 2013.

"We wish to thank the Office of the Chief Scientist for their participation in advancing this important new application of regenerative medicine," said Charles Irving, Chief Executive of Cell Cure. "We anticipate that OpRegen(R) will make a real difference in the quality of life of the aging population in many industrialized countries," he noted, "and hence it is a strategic investment for not only Israel, but the world as a whole."

AMD is a severe form of acute vision loss and the leading cause of blindness in older people. It affects that part of the retina which is most critical in everyday tasks, such as reading and recognizing faces. "I join with Dr. Irving in thanking OCS for its generous support in accelerating these advances in stem cell biology into the clinic," said Prof. Reubinoff.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Jan 13 2017

Saving Children in the Nick of Time at Hadassah

When a four-year-old, blue and critically ill, was rushed into the pediatric emergency room at Hadassah Hospital Mount Scopus, Dr. David Rekhtman, head of the ER, and his team deciphered that the child had somehow consumed methadone.

READ MORE ›
alt_text

Friday, Jan 13 2017

Peace in Sight: An Israeli, Palestinian, and Hadassah Australia Collaboration

St. John of Jerusalem Eye Hospital, in collaboration with Hadassah Medical Center, has received a €500,000 grant from the European Union to establish a genetic research unit to serve the Palestinian communities.

READ MORE ›
alt_text

Friday, Jan 13 2017

A Second Chance at Life, Thanks to Hadassah’s Heart Institute

A resident of a rural settlement called Dishon, established by Libyan Jewish immigrants in 1953, Eyal Amar, age 47, was rather young to suffer a devastating heart attack. Nevertheless, he did, but thanks to the courage and skill of the specialists at the Hadassah Medical Organization’s Heart Institute and their complex protocol to redesign his heavily damaged heart, Eyal is able to walk and breathe again.

READ MORE ›
alt_text

Tuesday, Jan 10 2017

From Locked Jaw to Osteoarthritis: Hadassah Discovery Leads to New Treatment

What began as a solution to locked jaw--temporomandibular joint (TMJ) disorder--has led to the creation of a novel non-opioid pharmaceutical candidate for the treatment of osteoarthritis pain, thanks to a Hadassah Medical Organization discovery and collaboration with colleagues at the Hebrew University and the Technion.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More